<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1202256889
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Ondansetron Kabi 2 MG/ML SOL. FOR INJ
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ONDANSETRON
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C ,  protect from Light
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        56.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Labesfal Laboratorios Almiro S.A., Fresenius Kabi Group" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Labesfal Laboratorios Almiro S.A., Fresenius Kabi Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 606]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALHAYA MEDICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Labesfal Laboratorios Almiro, S.A. 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A04AA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ondansetron belongs to a group of medicines called anti-emetics, drugs against feeling sick or being sick. Some medical treatment with medicines for treatment of cancer (chemotherapy) or radiotherapy can make you feel sick (nausea) or be sick (vomiting). Also after surgical treatment you can feel sick (nausea) or be sick (vomiting). Ondansetron may help to prevent or to stop these effects.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Ondansetron </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are hypersensitive to ondansetron or to other selective 5HT<sub>3</sub> receptor antagonists (e.g.granisetron, dolastron) or to any of the excipients (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are treated with apomorphine (drug to treat Parkinson&rsquo;s disease)</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, nurse or pharmacist before using Ondansetron</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have reacted hypersensitive to other medicines against feeling sick or being sick, such as granisetron or palonosetron.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a blockage in your gut or suffer from severe constipation. Ondansetron can impede the mobility of the lower gut.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any hepatic impairment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have undergone surgery to remove the palatine tonsils situated at the back of the throat (adenotonsillar surgery).if you have ever had heart problems, incl. an uneven heartbeat (arrhytmias). Ondansetron prolongs the QT interval (ECG sign of delayed repolarization of the heart following a heartbeat with the risk of life-threatening arrhythmias) in a dose-dependent manner.if you have problems with the levels of salts in your blood, such as potassium, sodium and magnesium</p><p>&nbsp;</p><p><strong>Other medicines and Ondansetron </strong></p><p>Tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>If you are taking tramadol (painkiller): ondansetron may reduce the analgesic effect of tramadol.</p><p>If you are taking phenytoin, carbamazepine (anti-epileptics) or rifampicin (antibiotic for tuberculosis): the ondansetron blood concentrations are decreased.</p><p>If you are taking cardiotoxic drugs (e.g. anthracyclines (cancer antibiotics such as doxorubicin, daunorubicin) or trastuzumab, a cancer medicine), antibiotics (such as erythromycin), antifungals (such as ketoconazole), antiarrhythmics (such as amiodarone) and beta blockers (drugs that slow heart rate such as atenolol or timolol): use of ondansetron with other QT prolonging drugs may result in an additional QT prolongation, i.e. increase the risk of arrhythmias.</p><p>If you are taking other serotonergic drugs such as selective serotonin reuptake inhibitors (SSRIs) or serotonin noradrenaline reuptake inhibitors (SNRIs) like sertraline or duloxetine (both are antidepressants): there are case reports describing patients with the so-called serotonin syndrome (e.g. hypervigilance and agitation, increased heart rate and blood pressure, tremor and overresponsive reflexes) following the concomitant use of ondansetron with other serotonergic drugs.</p><p>If you are taking apomorphine (drug to treat Parkinson&rsquo;s disease): apomorphine must not be used together with ondansetron, as there are case reports of profound hypotension (low blood pressure) and loss of consciousness when both drugs are concomitantly administered.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>You should not use Ondansetron during the first trimester of pregnancy. This is because Ondansetron can slightly increase the risk of a baby being born with cleft lip and/or cleft palate (openings or splits in the upper lip and/or the roof of the mouth). If you are already pregnant or breast-feeding, think you might be pregnant or are planning to have baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>If you are a woman of childbearing potential you may be advised to use effective contraception.</p><p><u>&nbsp;</u></p><p>Ondansetron passes into mother&rsquo;s milk. Therefore, mothers receiving ondansetron should NOT breast-feed.</p><p>Ask your doctor for advice before taking any medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Ondansetron has no effect on the ability to drive or use machines.</p><p>&nbsp;</p><p><strong>Ondansetron contains sodium</strong></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per ampoule, that is to say essentially &lsquo;sodium- free&lsquo;.</p><p>When the dose is greater than 6 ml it cannot be considered &lsquo;sodium-free&rsquo; and it should be taken into consideration by patients on a controlled sodium diet. At maximum daily dose (16 ml) this medicine contains 56 mg of sodium. This is equivalent to approximately 2.3% of the recommended daily dietary intake of sodium for an adult.<br />&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Method of administration</strong></p><p>Ondansetron is administered as injection into your vein or an injection into your muscle or, after dilution, as intravenous infusion (for a longer time). It will usually be given by a doctor or a nurse.</p><p>&nbsp;</p><p><strong>Dosage</strong></p><p>Adults (less than 75 years of age)</p><p>Your doctor will decide on the correct dose of ondansetron therapy for you.</p><p>The dose varies depending on your medicinal treatment (chemotherapy or surgery), on your liver function and on whether it is given by injection or infusion.</p><p>&nbsp;</p><p>In case of chemotherapy or radiotherapy the usual dose in adults is 8 &ndash; 32 mg ondansetron a day. A single dose greater than 16 mg must not be given.</p><p>&nbsp;</p><p>For treatment of post-operative nausea and vomiting usually a single dose of 4 mg ondansetron is administered. For prevention of post-operative nausea and vomiting usually a single dose of 4 mg ondansetron is administered.</p><p><em>&nbsp;</em></p><p>Children aged <u>&gt; </u>6 months and adolescents</p><p>In case of chemotherapy the usual dose is a single intravenous dose of 5 mg/m<sup>2</sup> (body area) immediately before chemotherapy. The intravenous dose must not exceed 8 mg.</p><p>&nbsp;</p><p>Children aged <u>&gt;</u>1 month and adolescents</p><p>For treatment of post-operative nausea and vomiting the usual dose is of 0.1 mg/kg (body weight). The maximum dose is 4 mg as an injection into a vein.</p><p>For prevention of post-operative nausea and vomiting the usual dose is of 0.1 mg/kg (body weight). The maximum dose is 4 mg as an injection into a vein. This will be given just before the operation.</p><p>&nbsp;</p><p><strong>Dosage adjustment</strong></p><p><em>Older people:</em></p><p>In case of chemotherapy the initial dosage should not exceed 8 mg for patients 75 years of age or older.</p><p>&nbsp;</p><p><em>Patients with hepatic impairment:</em></p><p>In patients having hepatic problems the dose has to be adjusted to a maximum daily dose of 8 mg ondansetron.</p><p>&nbsp;</p><p><em>Patients with renal impairment or poor sparteine/debrisoquine metabolism:</em></p><p>No alteration of daily dosage or frequency of dosing or route of administration is required.</p><p>&nbsp;</p><p><strong>Duration of treatment</strong></p><p>Your doctor will decide on the duration of ondansetron therapy for you.</p><p>After intravenous administration of Ondansetron the therapy may be continued with ondansetron tablets or suppositories for up to 5 days.</p><p>&nbsp;</p><p><strong>If you received more Ondansetron than you should</strong></p><p>Little is known at present<strong><em> </em></strong>about overdosage with ondansetron. Overdose increases the probability of side effects described in section 4. In a few patients, the following effects were observed after overdose: visual disturbances, severe constipation, low blood pressure, disturbance in heart rhythm and unconsciousness. In all cases, the symptoms disappeared completely.</p><p>&nbsp;</p><p>Your doctor or nurse will give you or your child Ondansetron so it is unlikely that you or your child will receive too much. If you think you or your child have been given too much or have missed a dose, tell your doctor or nurse.</p><p>&nbsp;</p><p>There is no specific antidote to ondansetron; for that reason, if overdose is suspected, only the symptoms should be treated.</p><p>Tell your doctor if any of these symptoms occur.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Ondansetron can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Tell your doctor or nurse immediately if you experience any of the following:</p><p>&nbsp;</p><p>Uncommon: may affect up to 1 in 100 people</p><p>- Chest pain, slow or uneven heartbeat</p><p>&nbsp;</p><p>Rare (may affect up to 1 in 1,000 people):</p><p>- Immediate allergic reactions like itchy rash, swelling of the eyelids, face, lips, mouth and tongue.</p><p>Not known: frequency cannot be estimated from the available data<br />- Myocardial ischemia<br />Signs include:<br />sudden chest pain or<br />chest tightness<br />&nbsp;</p><p>Other side effects include:</p><p>&nbsp;</p><p>Very common: may affect more than 1 in 10 people</p><p>- headache</p><p>&nbsp;</p><p>Common: may affect up to 1 in 10 people</p><p>- constipation</p><p>- sensation of warmth or flushing</p><p>- irritation and redness at the site of injection</p><p>&nbsp;</p><p>Uncommon: may affect up to 1 in 100 people</p><p>- low blood pressure, which can make you feel faint or dizzy</p><p>- fits</p><p>- unusual body movements or shaking</p><p>- hiccups</p><p>- interference with liver function tests</p><p>&nbsp;</p><p>Rare: may affect up to 1 in 1,000 people</p><p>- feeling dizzy or light headed</p><p>- blurred vision</p><p>- disturbance in heart rhythm (sometimes causing a sudden loss of consciousness)</p><p>&nbsp;</p><p>Very rare: may affect up to 1 in 10,000 people</p><p>- temporary blindness (most resolved within 20 minutes)</p><p>- skin rash, e.g. red spots or lumps under the skin (hives) anywhere on the body which can transform into large blisters</p><p>&nbsp;</p><p>Additional side effects in children and adolescents</p><p>The side effects observed in children and adolescents were comparable to that seen in adults.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Keep the ampoules in the outer carton in order to protect from light.<br />Do not store above 30˚C Prescription only. Single use only, discard any unused contents.<br />Do not use this medicine after the expiry date, which is stated on the ampoule label and carton.<br />The diluted solutions should be stored protected from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is ondansetron.</p><p>&nbsp;</p><p>Each ampoule with 2 ml contains 4 mg ondansetron.</p><p>Each ampoule with 4 ml contains 8 mg ondansetron.</p><p>&nbsp;</p><p>Each milliliter contains 2 mg ondansetron as ondansetron hydrochloride dihydrate.</p><p>&nbsp;</p><p>The other ingredients are sodium chloride, sodium citrate dihydrate, citric acid monohydrate and water for injections.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Ondansetron Kabi is a clear and colourless solution in colourless glass ampoules containing 2 ml or 4 ml of solution for injection.
	
Pack sizes: 1, 5 and 10 ampoules
	
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Labesfal Laboratorios Almiro S.A.,</p><p>Zona Industrial do Lagedo, 3465-157</p><p>Santiago de Besterios</p><p>Portugal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Jan 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:justify">ينتمي دواء &quot;أوندانسيترون&quot; إلى مجموعة من الأدوية المعروفة باسم (مُضادات التقيؤ، أو الأدوية المضادة للشعور بالاعتلال أو كونك مريضًا). فقد تؤدي بعض الأدوية الطبيَّة، جنبًا إلى جنب مع العلاجات المُستخدمة لعلاج السرطان (العلاج الكيميائي) أو العلاج الإشعاعي، إلى الشعور بالإعياء (الغثيان) أو الشعور بالسقم (القيء). كما يمكن أيضًا الشعور بالإعياء (الغثيان) أو الشعور بالسقم (القيء) بعد العلاجات الجراحيَّة. وقد يساعد دواء &quot;أوندانسيترون &quot; على منع تلك الآثار أو إيقافها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت شديد الحساسية تجاه &quot;الأوندانسيترون&quot; أو مُضادات مُستقبلات (5HT3) الانتقائية الأخرى، (مثل: الجرانيسترون والدولاسيترون)، أو تجاه أي من مكوناته غير الأساسيَّة (المُدرجة في القسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعالَج باستخدام &quot;الأبو مورفين&quot; (وهو أحد الأدوية المستخدمة لعلاج مرض باركنسون).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاحتياطات والمحاذير</strong></p><p dir="RTL">لابد من استشارة الطبيب أو الصيدلي أو الممرضة قبل استخدام دواء &quot;أوندانسيترون&quot; بشأن أي مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من فرط الحساسية تجاه الأدوية الأخرى المستخدمة لعلاج الشعور بالإعياء أو المرض (مثل: الجرانيسترون أو البالونسيترون).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انسداد في الأمعاء أو الإمساك الشديد، حيث يمكن للأوندانسيترون إعاقة حركة الأمعاء السفلية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي اختلال كبدي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت لتدخل جراحي لإزالة اللوزتين الحنكيتين الموجودتين في الجزء الخلفي من الحلق (جراحة الغدد اللوزيَّة)؛ وإذا كنت قد عانيت من أي مشكلات في القلب بما في ذلك عدم انتظام ضربات القلب (اضطراب نبض القلب)؛ حيث يعمل &quot;الأوندانسيترون&quot; على إطالة (فترة QT)، أي (إشارة مُخطط كهربية القلب على تأخر عودة استقطاب القلب بعد النبض مع وجود خطر عدم انتظام ضربات القلب الذي يهدد الحياة)، وذلك بصورة تعتمد على الجرعة. وإذا كنت تعاني من مشكلات مع مستويات الأملاح في الدم (مثل: البوتاسيوم، والصوديوم، والماغنسيوم).</p><p dir="RTL"><strong>استخدام دواء &quot;أوندانسيترون &quot; مع الأدوية الأخرى </strong></p><p dir="RTL">لابد من استشارة الطبيب أو الممرضة أو الصيدلي، إذا كنت تستخدم أو قد استخدمت حديثًا أو قد تستخدم أي أدوية أخرى، بما في ذلك الأدوية التي حصلت عليها بدون وصفة طبيَّة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول الترامادول (مسكن الآلام): قد يعمل دواء &quot;أوندانسيترون&quot; على الحد من التأثير المُسكِّن للترامادول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول الفينيتوين أو الكاربازيبين (مضادات الصرع) أو الريفامبيسين (مضاد حيوي لمرض السل): حيث تقل تركيزات الأوندانسيترون في الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول الأدوية السامة للقلب، مثل: &quot;الأنثراسيكلين&quot; (وهي مضادات حيوية للسرطان، مثل: الدوكسوروبيسين، والداونوروبيسين)، أو &quot;التراستوزوماب&quot; (وهو دواء للسرطان)؛ والمضادات الحيوية (مثل: الإيريثرومايسين)؛ ومضادات الفطريات (مثل: الكيتوكونازول)؛ ومضادات اضطراب النظم القلبي (مثل: الأميودارون)؛ وحاضرات بيتا (وهي الأدوية التي تعمل على إبطاء معدل ضربات القلب، مثل: الأتينولول أو التيمولول)؛ حيث قد يؤدي استخدام الأوندانسيترون مع الأدوية الأخرى التي تستخدم لإطالة (فترة QT) إلى إطالة إضافية لـ (فترة QT)، أي زيادة خطر عدم انتظام ضربات القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية أخرى من أدوية هرمون السيروتونين، مثل: المثبطات الانتقائية لإعادة امتصاص السيروتونين (SSRIs)، أو مثبطات إعادة امتصاص السيروتونين والنورأدرينالين (SNRIs) مثل: السيرترالين أو الدولوكستين (وكلاهما من مضادات الاكتئاب)؛ حيث تناولت بعض التقارير حالات لمرضى يعانون مما يُعرف باسم &quot;متلازمة السيروتونين&quot; (مثل: فرط اليقظة والإثارة، وزيادة معدل ضربات القلب وضغط الدم والارتعاش، وفرط الاستجابة) بعد استخدام الأوندانسيترون بالتزامن مع أدوية هرمون السيروتونين الأخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول الأبو مورفين (وهو الدواء المستخدم لعلاج مرض باركنسون): فيجب ألا يتم استخدام &quot;الأبو مورفين&quot; مع &quot;الأوندانسيترون&quot;، حيث أشارت بعض تقارير الحالات إلى انخفاض كبير في ضغط الدم (هبوط ضغط الدم) وفقدان الوعي عند تناول العقارين كليهما في الوقت ذاته.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">ينبغي عدم استخدام دواء &quot;أوندانسيترون &quot; خلال الثلث الأول من فترة الحمل، نظراً لأن دواء &quot;أوندانسيترون&quot; يمكنه أن يزيد قليلًا من خطر ولادة طفل بشفة مشقوقة و/أو حنك مشقوق (فتحات أو شقوق في الشفة العليا و/أو سقف الفم). فإذا كنتِ حاملًا أو ترضعين رضاعة طبيعية بالفعل، أو تعتقدين بأنك من المحتمل أن تكوني حاملًا أو تخططين لإنجاب طفل، فلابد من استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">وإذا كنتِ من النساء القادرات على الإنجاب، فيُنصَح باستخدام وسائل منع الحمل الفعالة.</p><p dir="RTL">كما يمر &quot;الأوندانسيترون&quot; خلال حليب الأم، لذا، ينبغي على الأمهات ممن يتلقين علاجًا باستخدام الأوندانسيترون عدم الاعتماد على الرضاعة الطبيعية.</p><p dir="RTL">لابد من استشارة الطبيب قبل تناول أي دواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا يؤثِّر &quot;الأوندانسيترون&quot; على القدرة على القيادة أو استخدام الآلات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أوندانسيترون كابي يحتوي على الصوديوم</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي هذا المنتج الطبي على أقل من 1 مليمول صوديوم (23 مجم) لكل أمبولة ، وهذا يعني بشكل أساسي &quot;خالٍ من الصوديوم&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما تكون الجرعة أكبر من 6 مل ، لا يمكن اعتبارها &quot;خالية من الصوديوم&quot; ويجب أخذها في الاعتبار من قبل المرضى الذين يتبعون نظامًا غذائيًا للتحكم بالصوديوم. في الجرعة القصوى (16 مل) يحتوي هذا الدواء على 56 ملغ من الصوديوم. وهذا يعادل ما يقرب من 2.3٪ من المقدار الغذائي اليومي الموصى به من الصوديوم للبالغين.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم تناول الدواء عن طريق الحقن في الوريد (داخل الوريد) أو عن طريق الحقن في العضل، أو يُستخدم بعد التخفيف للتسريب الوريدي داخل الوريد (لمدة زمنية أطول)، وعادة ما يُعطيه الطبيب أو الممرضة. &nbsp;&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL"><strong>البالغون (أقل من سن 75 سنة)</strong></p><p dir="RTL">سوف يقرر طبيبك الجرعة الصحيحة لك من دواء الأوندانسيترون.</p><p dir="RTL">تختلف الجرعة بحسب علاجك الطبي (علاج كيميائي أو جراحي)، وحسب وظائف الكبد، وما إذا كانت تُعطى عن طريق الحقن أو التسريب الوريدي.</p><p dir="RTL">وفي حالة تلقي العلاج الكيميائي أو الإشعاعي، تكون الجرعة المعتادة مع البالغين 8-32 ملجم من الأوندانسيترون يوميًا؛ وينبغي عدم إعطاء جرعة واحدة أكبر من 16 ملجم.</p><p dir="RTL">وفي علاج حالات الإعياء والقيء التي تحدث بعد إجراء العمليات الجراحية، عادة ما تُعطى جرعة واحدة قدرها 4 ملجم من الأوندانسيترون؛ ومن أجل الوقاية من الغثيان والقيء الذي يلي العمليات الجراحية، تُعطى جرعة واحدة قدرها 4 ملجم من الأوندانسيترون.</p><p dir="RTL"><strong>الأطفال ممن تزيد أعمارهم عن 6 أشهر والمراهقون</strong></p><p dir="RTL">في حالة تلقي العلاج الكيميائي، تكون الجرعة المعتادة هي جرعة واحدة عن طريق الوريد تبلغ 5 ملجم/متر<sup>2</sup> (من مساحة الجسم) قبل تلقي العلاج الكيميائي مباشرة؛ وينبغي ألا تتجاوز الجرعة الوريدية 8 ملجم.</p><p dir="RTL"><strong>الأطفال ممن تزيد أعمارهم عن شهر واحد والمراهقون</strong></p><p dir="RTL">من أجل علاج الإعياء والقيء بعد إجراء العمليات الجراحيَّة، تكون الجرعة المعتادة 0.1 ملجم/كجم (من وزن الجسم)؛ ويتحدد الحد الأقصى للحقن في الوريد في 4 ملجم.</p><p dir="RTL">من أجل الوقاية من الإصابة بالغثيان والقيء بعد إجراء العمليات الجراحية، تكون الجرعة المعتادة 0.1 ملجم/كجم من وزن الجسم؛ ويتحدد الحد الأقصى للحقن في الوريد في 4 ملجم. وسوف تُعطى هذه الجرعة قبل إجراء العملية.</p><p dir="RTL"><strong>ضبط الجرعة</strong></p><p dir="RTL"><strong>كبار السن</strong></p><p dir="RTL">في حال تلقي العلاج الكيميائي، ينبغي ألا تتجاوز الجرعة الأوليَّة 8 ملجم للمرضى ممن تبلغ أعمارهم 75 عامًا أو أكثر.</p><p dir="RTL"><strong>المرضى ممن يعانون من اختلال كبدي</strong></p><p dir="RTL">ينبغي ضبط الجرعة بحيث يكون الحد الأقصى للجرعة اليوميَّة 8 ملجم من الأوندانسيترون لدى المرضى ممن يُعانون من مشكلات في الكبد.</p><p dir="RTL"><strong>المرضى ممن يعانون من اضطراب كُلوي أو استقلاب ضعيف للأسبارتئين/ديبرسوكوين</strong></p><p dir="RTL">لا يلزم تغيير الجرعة اليوميَّة أو عدد مرات إعطاء الدواء أو طريقة إعطاءه.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مدة العلاج</strong></p><p dir="RTL">سوف يقرر طبيبك مدة علاجك باستخدام دواء الأوندانسيترون.</p><p dir="RTL">وبعد أخذ دواء &quot;أوندانسيترون &quot; عن طريق الوريد، قد يستمر العلاج باستخدام أقراص أو أقماع الأوندانسيترون لمدة 5 أيام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تعاطي جرعة أكثر مما يجب من دواء &quot;أوندانسيترون&quot;</strong></p><p dir="RTL">لا يتوافر كثير من المعلومات حالياً عن الجرعة الزائدة من الأوندانسيترون؛ وبشكل عام، تزيد الجرعة الزائدة من احتمالية حدوث الآثار الجانبية الموضَّحة في القسم 4. وقد لوحِظَ في عدد قليل من المرضى التأثيرات التالية بعد أخذ جرعة زائدة من الدواء: اضطرابات في الرؤية، وإمساك شديد، وانخفاض في ضغط الدم، واضطراب ضربات القلب، وفقد الوعي. ولقد اختفت الأعراض تمامًا في جميع الحالات.</p><p dir="RTL">وسوف يتم إعطاء دواء &quot;أوندانسيترون &quot; لك أو لطفلك من قبل طبيبك أو الممرضة، لذا، فمن غير المرجَّح أن تتلقى جرعة زائدة أنت أو طفلك. وإذا كنت تعتقد أنك أو طفلك قد تعاطيت جرعة زائدة من الدواء أو فاتتك جرعة، فلابد من استشارة الطبيب أو الممرضة.</p><p dir="RTL">ولا يوجد ترياق محدد للأوندانسيترون؛ ولهذا السبب، إذا تم الاشتباه بجرعة زائدة، يتم معالجة الأعراض فقط.</p><p dir="RTL">ولذلك، لابد من إخبار الطبيب حال حدوث أي من هذه الأعراض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">من الممكن أن يتسبب دواء &quot;أوندانسيترون&quot; في إحداث بعض الآثار الجانبيَّة مثله مثل جميع الأدوية، وإن لم تكن هذه الأعراض تصيب جميع المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو ممرضتك على الفور إذا واجهت أيًا مما يلي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير شائعة: في أكثر من 1 لكل 1000 مريض، ولكن أقل من 1 من كل 100 مرضى.</p><p dir="RTL">- ألم في الصدر ، بطء أو عدم انتظام ضربات القلب.</p><p dir="RTL">نادرة: في أكثر من 1 لكل 10000 مريض، ولكن أقل من 1 من كل 1000 مرضى.</p><p dir="RTL">- ردود فعل تحسسية فورية مثل طفح جلدي وحكة وتورم في الجفون والوجه والشفتين والفم واللسان.</p><p dir="RTL">غير معروفة: لا يمكن تقدير التكرار من البيانات المتاحة</p><p dir="RTL">- &nbsp;نقص تروية عضلة القلب</p><p dir="RTL">تشمل العلامات ما يلي:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . ألم مفاجئ في الصدر أو</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . ضيق في الصدر</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويُصنَّف حدوث الآثار الجانبيَّة في الفئات الآتية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة جدًا: في أكثر من 1 لكل 10 مرضى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع.</p><p dir="RTL">شائعة: في أكثر من 1 لكل 100 مريض، ولكن أقل من 1 من كل 10 مرضى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بالدفء أو الاحمرار.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيُّج واحمرار في مكان الحقن.</p><p dir="RTL">غير شائعة: في أكثر من 1 لكل 1000 مريض، ولكن أقل من 1 من كل 100 مرضى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم مما يجعلك تشعر بالإغماء أو الدوار.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في الصدر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات جسدية غير معتادة أو اهتزازات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة الفواق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضارب اختبارات وظائف الكبد.</p><p dir="RTL">نادرة: في أكثر من 1 لكل 10000 مريض، ولكن أقل من 1 من كل 1000 مرضى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار أو الدوخة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرؤية الضبابية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في النظم القلبي (مما يسبب أحيانًا فقدان الوعي المفاجئ).</p><p dir="RTL">نادرة جدًا: أقل من 1 من بين 10000 مريض</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان البصر المؤقت (يُحل في غضون 20 دقيقة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، على سبيل المثال، ظهور بقع حمراء أو كتل تحت الجلد (الشرى) في أي مكان على الجسم، والتي يمكن أن تتحول إلى بثور كبيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية إضافية في الأطفال والمراهقون</p><p dir="RTL">كانت الآثار الجانبية التي لوحظت لدى الأطفال مماثلة لتلك التي شوهدت في البالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيفيَّة تخزين دواء &quot;أوندانسيترون كابي &quot;</strong></p><p>- احفظ هذا الدواء بعيدًا عن أنظار ومتناول الأطفال.</p><p>- احتفظ بالأمبولات في علبة الكرتون الخارجية للحفاظ عليها من الضوء.</p><p>- لا تخزن في درجة حرارة أكثر من 30 درجة مئوية. يصرف بوصفة طبية فقط . للاستخدام مرة واحدة فقط ، تجاهل أي محتويات غير مستخدمة.</p><p>- لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على ملصق الأمبولة والكرتون.</p><p>&nbsp;</p><p>يجب تخزين المحاليل المخففة محمية من الضوء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل أمبول (2 ملل) على 4 ملجم من الأوندانسيترون.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل أمبول (4 ملل) على 8 ملجم من الأوندانسيترون.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل مليليتر على 2 ملجم من الأوندانسيترون في صورة هيدروكلوريد ثنائي هيدرات الأوندانسيترون.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: كلوريد الصوديوم، وأحادي هيدرات حامض الستريك، وماء للحقن. &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دواء &quot;أوندانسيترون&quot; هو محلول رائق عديم اللون في أمبولات زجاجية عديمة اللون، تحتوي على 2 ملل أو 4 ملل من محلول للحقن.</p><p dir="RTL"><strong>أحجام العبوات</strong>: 1 و5 و10 أمبولات.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify"><strong>الشركة صاحبة رخصة التسويق</strong></p><p dir="RTL" style="text-align:justify">[يُستكمل على الصعيد الوطني]</p><p dir="RTL" style="text-align:justify"><strong>الشركة المُصنعة</strong></p><p dir="RTL" style="text-align:justify">شركة لابيسفال لابوراتوريز ألميرو، شركة محدودة، لاجيدو، 157-3465 سانتياغو دي بيستيريوس، البرتغال.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            شهر (1) / عام (2022م)
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ondansetron 2 mg/ml solution for injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml solution for injection contains:
Ondansetron hydrochloride dihydrate equivalent to 2 mg ondansetron.
Each ampoule with 2 ml contains 4 mg ondansetron.
Each ampoule with 4 ml contains 8 mg ondansetron.
1 ml solution for injection contains 3.34 mg of sodium as sodium citrate dihydrate and sodium chloride.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection
Clear and colourless solution

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Adults:</em></p><p>Ondansetron is indicated for management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy</p><p>&nbsp;</p><p>Ondansetron is also indicated for the prevention and treatment of post-operative nausea and vomiting (PONV).</p><p><strong>&nbsp;</strong></p><p><em>Paediatric Population:</em></p><p>Ondansetron is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged &ge;6 months, and for prevention and treatment of PONV in children aged &ge;1 month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Chemotherapy and radiotherapy induced nausea and vomiting (CINV and RINV)</u></p><p>&nbsp;</p><p><em>Adults</em></p><p>The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The route of administration and dose of Ondansetron should be flexible in the range of 8-32 mg a day and selected as shown below</p><p><u>Emetogenic chemotherapy and radiotherapy</u></p><p>For patients receiving emetogenic chemotherapy or radiotherapy ondansetron can be given either by intravenous or oral administration or intramuscular administration.</p><p>The recommended dose of ondansetron is 8 mg administered as a slow intravenous injection in not less than 30 seconds or intramuscular injection, immediately before treatment.</p><p>&nbsp;</p><p>Oral or rectal treatment is recommended to protect against delayed or prolonged emesis after the first 24 hours.</p><p>For oral or rectal administration refer to the SmPC of ondansetron tablets and suppositories, respectively.</p><p><em>&nbsp;</em></p><p><u>Highly emetogenic chemotherapy e.g. high-dose cisplatin</u></p><p>Ondansetron may be administered as a single dose of 8 mg by slow intravenous injection (in not less than 30 seconds) or intramuscular injection immediately before chemotherapy. Doses of greater than 8 mg and up to a maximum of 16 mg of ondansetron may only be given by intravenous infusion diluted in 50 to 100 ml of saline or other compatible infusion fluid and infused over not less than 15 minutes. A single dose greater than 16 mg must not be given due to dose dependent increase of QT-prolongation risk (see sections 4.4, 4.8 and 5.1).</p><p>&nbsp;</p><p>For management of highly emetogenic chemotherapy, a dose of 8&nbsp;mg may be administered by slow intravenous injection in not less than 30 seconds, followed by two further intravenous doses of 8&nbsp;mg four hours apart, or by a constant infusion of 1&nbsp;mg/hour for up to 24&nbsp;hours.</p><p>&nbsp;</p><p>The efficacy of Ondansetron in highly emetogenic chemotherapy may be enhanced by the addition of a single intravenous dose of dexamethasone sodium phosphate, 20&nbsp;mg administered prior to chemotherapy.</p><p>&nbsp;</p><p>Oral or rectal treatment is recommended to protect against delayed or prolonged emesis after the first 24 hours.</p><p>For oral or rectal administration refer to the SmPC of ondansetron tablets and suppositories, respectively.</p><p>&nbsp;</p><p><em>Paediatric Population</em></p><p>CINV in children aged &ge;6 months and adolescents:</p><p>The dose for CINV can be calculated based on body surface area (BSA) or weight &ndash; see below. In paediatric clinical studies, ondansetron was given by intravenous infusion diluted in 25 to 50 ml of saline or other compatible infusion fluid (see section 6.6) and infused over not less than 15 minutes.</p><p>&nbsp;</p><p>Weight-based dosing results in higher total daily doses compared to BSA-based dosing (see sections 4.4)</p><p>&nbsp;</p><p>Ondansetron should be diluted in 5% dextrose or 0.9% sodium chloride or other compatible infusion fluid (see section 6.6.) and infused intravenously over not less than 15 minutes.</p><p>&nbsp;</p><p>There are no data from controlled clinical trials on the use of Ondansetron in the prevention of chemotherapy-induced delayed or prolonged nausea and vomiting.</p><p>&nbsp;</p><p>There are no data from controlled clinical trials on the use of Ondansetron for radiotherapy-induced nausea and vomiting in children.</p><p>&nbsp;</p><p>Dosing by BSA:</p><p>Ondansetron should be administered immediately before chemotherapy as a single intravenous dose of 5 mg/m<sup>2</sup>. The intravenous dose must not exceed 8 mg..</p><p>Oral dosing can commence twelve hours later and may be continued for up to 5 days. See Table 1 below.</p><p>The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p>&nbsp;</p><p>Table 1: BSA-based dosing for Chemotherapy induced nausea and vomiting - Children aged &ge;6 months and adolescents<sup>a</sup></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>BSA</p></td><td style="vertical-align:top"><p>Day 1<sup>b,c</sup></p></td><td style="vertical-align:top"><p>Days 2-6<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>&lt; 0.6 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2 </sup>i.v. plus 2 mg syrup after 12 hours</p></td><td style="vertical-align:top"><p>2 mg syrup every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p><u>&gt;</u> 0.6 m<sup>2</sup> to &le; 1.2 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2 </sup>i.v. plus 4 mg syrup or tablet after 12 hours</p></td><td style="vertical-align:top"><p>4 mg syrup or tablet every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>&gt;1.2 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2 </sup>or 8 mg i.v. plus 8 mg syrup or tablet after 12 hours</p></td><td style="vertical-align:top"><p>8 mg syrup or tablet every 12 hours</p></td></tr></tbody></table><p>a Not all pharmaceutical forms may be available.</p><p>b The intravenous dose must not exceed 8 mg.</p><p>c The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p>&nbsp;</p><p>Dosing by bodyweight:</p><p>Weight-based dosing results in higher total daily doses compared to BSA-based dosing (see sections 4.4)</p><p>Ondansetron should be administered immediately before chemotherapy as a single intravenous dose of 0.15 mg/kg. The single intravenous dose must not exceed 8 mg.</p><p>Two further intravenous doses may be given in 4-hourly intervals. The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p>Oral dosing can commence twelve hours later and may be continued for up to 5 days. See Table 2 below.</p><p>&nbsp;</p><p>Table 2: Weight-based dosing for Chemotherapy induced nausea and vomiting - Children aged &ge;6 months and adolescents<sup>a</sup></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Weigth</p></td><td style="vertical-align:top"><p>Day 1<sup>b,c</sup></p></td><td style="vertical-align:top"><p>Days 2-6<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" alt="LESS-THAN OR EQUAL TO (8804)"
   style='width:9pt;height:9pt;mso-wrap-distance-left:1.5pt;
   mso-wrap-distance-right:1.5pt'>
   <v:imagedata src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
    o:href="http://renderer.medicines.org.uk/images/entities/LESS-THAN_OR_EQUAL_TO.gif"/>
  </v:shape><![endif]--><img width="12" height="12" alt="LESS-THAN OR EQUAL TO (8804)" src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />10 kg</p></td><td style="vertical-align:top"><p>Up to 3 doses of 0.15 mg/kg i.v. every 4 hours</p></td><td style="vertical-align:top"><p>2 mg syrup every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 10 kg</p></td><td style="vertical-align:top"><p>Up to 3 doses of 0.15 mg/kg i.v. every 4 hours</p></td><td style="vertical-align:top"><p>4 mg syrup or tablet every 12 hours</p></td></tr></tbody></table><p>a Not all pharmaceutical forms may be available.</p><p>b The intravenous dose must not exceed 8 mg.</p><p>c The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p>&nbsp;</p><p><em>Elderly:</em></p><p>In patients 65 to 74 years of age, the dose schedule for adults can be followed. All intravenous doses should be diluted in 50-100 ml of saline or other compatible infusion fluid (see section 6.6) and infused over 15 minutes.</p><p>&nbsp;</p><p>In patients 75 years of age or older, the initial intravenous dose of Ondansetron should not exceed 8 mg. All intravenous doses should be diluted in 50-100 ml of saline or other compatible infusion fluid (see section 6.6) and infused over 15 minutes.</p><p>&nbsp;</p><p>The initial dose of 8 mg may be followed by two further intravenous doses of 8 mg, infused over 15 minutes and given no less than four hours apart (see section 5.2).</p><p><em>&nbsp;</em></p><p><em>Patients with renal impairment</em></p><p>No alteration of daily dosage or frequency of dosing, or route of administration are required.</p><p><em>Patients with hepatic impairment</em></p><p>Clearance of Ondansetron is significantly reduced and serum half-life significantly prolonged in subjects with moderate or severe impairment of hepatic function. In such patients, a total daily dose of 8 mg should not be exceeded.</p><p>&nbsp;</p><p><em>Patients with poor sparteine/debrisoquine metabolism</em></p><p>The elimination half-life of ondansetron is not altered in subjects classified as poor</p><p>metabolisers of sparteine and debrisoquine. Consequently, in such patients repeat dosing will give drug exposure levels no different from those of the general population. No alteration of daily dosage or frequency of dosing are required.</p><p>&nbsp;</p><p><u>Post-operative nausea and vomiting (PONV)</u></p><p>&nbsp;</p><p><em>Adults:</em></p><p><em>Prevention of PONV</em></p><p>For prevention of post-operative nausea and vomiting, the recommended dose of</p><p>Ondansetron injection is a single dose of 4 mg by slow intravenous injection or intramuscular injection at the induction of anaesthesia.</p><p>&nbsp;</p><p><em>Treatment of established PONV</em></p><p>For treatment of established PONV a single dose of 4&nbsp;mg given by slow intravenous injection or intramuscular injection is recommended.</p><p>&nbsp;</p><p><em>Paediatric population:</em></p><p>Post-operative nausea and vomiting in children aged &ge;1 month and adolescents</p><p>&nbsp;</p><p><em>For prevention of PONV</em> in paediatric patients having surgery performed under general anaesthesia, a single dose of Ondansetron may be administered by slow intravenous injection (not less than 30 seconds) at a dose 0.1 mg/kg up to a maximum of 4 mg either prior to, at or after induction of anaesthesia.</p><p><em>For the treatment of PONV</em> after surgery in paediatric patients having surgery performed under general anaesthesia, a single dose of Ondansetron may be administered by slow intravenous injection (not less than 30 seconds) at a dose of 0.1&nbsp;mg/kg up to a maximum of 4&nbsp;mg.</p><p>There are no data on the use of Ondansetron for treatment of postoperative vomiting in children below 2 years of age.</p><p>&nbsp;</p><p><em>Elderly:</em></p><p>There is limited experience in the use of Ondansetron in the prevention and treatment of post-operative nausea and vomiting (PONV) in older people, however ondansetron is well tolerated in patients over 65 years receiving chemotherapy.</p><p>&nbsp;</p><p><u>Special Populations</u></p><p>&nbsp;</p><p><em>Patients with renal impairment</em></p><p>No alteration of daily dosage or frequency of dosing, or route of administration is required.</p><p>&nbsp;</p><p><em>Patients with hepatic impairment</em></p><p>Clearance of Ondansetron is significantly reduced and serum half life significantly prolonged in subjects with moderate or severe impairment of hepatic function. In such patients a total daily dose of 8&nbsp;mg (orally or parenterally) should not be exceeded.</p><p><em>Patients with poor sparteine/debrisoquine metabolism</em></p><p>The elimination half-life of ondansetron is not altered in subjects classified as poor metabolisers of sparteine and debrisoquine. Consequently in such patients repeat dosing will give drug exposure levels no different from those of the general population. No alteration of daily dosage or frequency of dosing is required.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Concomitant use with apomorphine (see section 4.5).

Hypersensitivity to any component of the preparation.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5HT3 receptor antagonists.</p><p>&nbsp;</p><p>Respiratory events should be treated symptomatically and clinicians should pay particular attention to them as precursors of hypersensitivity reactions.</p><p>&nbsp;</p><p>Ondansetron prolongs the QT interval in a dose-dependent manner (see section 5.1). In addition, post-marketing cases of Torsade de Pointes have been reported in patients using ondansetron. Avoid ondansetron in patients with congenital long QT syndrome. Ondansetron should be administered with caution to patients who have or may develop prolongation of QTc, including patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias or patients taking other medicinal products that lead to QT prolongation or electrolyte abnormalities.</p><p>&nbsp;</p><p>Hypokalemia and hypomagnesemia should be corrected prior to ondansetron administration.</p><p>&nbsp;</p><p>There have been post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron and other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRI) and serotonin noradrenaline reuptake inhibitors (SNRIs)). If concomitant treatment with ondansetron and other serotonergic drugs is clinically warranted, appropriate observation of the patient is advised.</p><p>&nbsp;</p><p>As ondansetron is known to increase large bowel transit time, patients with signs of sub-acute intestinal obstruction should be monitored following administration.</p><p><strong><em>&nbsp;</em></strong></p><p>In patients with adenotonsillar surgery prevention of nausea and vomiting with ondansetron may mask occult bleeding. Therefore, such patients should be followed carefully after ondansetron.</p><p><strong><em>&nbsp;</em></strong></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per ampoule, that is to say essentially &lsquo;sodium- free&lsquo;.</p><p><strong><em>&nbsp;</em></strong></p><p><em>Paediatric Population:</em></p><p>&nbsp;</p><p>Paediatric patients receiving ondansetron with hepatotoxic chemotherapeutic agents should be monitored closely for impaired hepatic function.</p><p>&nbsp;</p><p>CINV</p><p>When calculating the dose on an mg/kg basis and administering three doses at 4-hour intervals, the total daily dose will be higher than if one single dose of 5 mg/m<sup>2 </sup>followed by an oral dose is given. The comparative efficacy of these two different dosing regimes has not been investigated in clinical trials. Cross trial comparing indicate similar efficacy for both regimes (see section 5.1)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence that ondansetron either induces or inhibits the metabolism of other drugs commonly coadministered with it. Specific studies have shown that there are no interactions when ondansetron is administered with alcohol, temazepam, furosemide, alfentanil, tramadol, morphine, lidocaine, thiopental or propofol.</p><p>&nbsp;</p><p>Ondansetron is metabolised by multiple hepatic cytochrome P-450 enzymes: CYP3A4, CYP2D6 and CYP1A2. Due to the multiplicity of metabolic enzymes capable of metabolising ondansetron, enzyme inhibition or reduced activity of one enzyme (e.g. CYP2D6 genetic deficiency) is normally compensated by other enzymes and should result in little or no significant change in overall ondansetron clearance or dose requirement.</p><p>&nbsp;</p><p>Caution should be exercised when ondansetron is coadministered with drugs that prolong the QT interval and/or cause electrolyte abnormalities. (See section 4.4).</p><p>&nbsp;</p><p>Use of Ondansetron with QT prolonging drugs may result in additional QT prolongation. Concomitant use of ondansetron with cardiotoxic drugs (e.g. anthracyclines (such as doxorubicin, daunorubicin) or trastuzimab), antibiotics (such as erythromycin), antifungals (such as ketoconazole), antiarrhythmics (such as amiodarone) and beta blockers (such as atenolol or timolol) may increase the risk of arrhythmias. (See section 4.4).</p><p>&nbsp;</p><p>There have been post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron and other serotonergic drugs (including SSRIs and SNRIs). (See section 4.4)</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Apomorphine</em></strong></p><p>Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Phenytoin, Carbamazepine and Rifampicin</em></strong></p><p>In patients treated with potent inducers of CYP3A4 (i.e. phenytoin, carbamazepine, and rifampicin), the oral clearance of ondansetron was increased and ondansetron blood</p><p>concentrations were decreased.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Tramadol</em></strong></p><p>Data from small studies indicate that ondansetron may reduce the analgesic effect of tramadol.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential </u></p><p><u>&nbsp;</u></p><p>Women of childbearing potential should consider the use of contraception.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Based on human experience from epidemiological studies, ondansetron is suspected to cause orofacial malformations when administered during the first trimester of pregnancy.</p><p>In one cohort study including 1.8 million pregnancies, first trimester ondansetron use was associated with an increased risk of oral clefts (3 additional cases per 10 000 women treated; adjusted relative risk, 1.24, (95% CI 1.03-1.48)).</p><p>&nbsp;</p><p>The available epidemiological studies on cardiac malformations show conflicting results.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproducive toxicity.</p><p>&nbsp;</p><p>Ondansetron should not be used during the first trimester of pregnancy.</p><p><s><u>&nbsp;</u></s></p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>Tests have shown that ondansetron passes into the milk of lactating animals. It is therefore recommended that mothers receiving ondansetron should not breast-feed their babies.</p><p>&nbsp;</p><p>Fertility</p><p>There is no information on the effects of ondansetron on human fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>In psychomotor testing ondansetron does not impair performance nor cause sedation. No detrimental effects on such activities are predicted from the pharmacology of ondansetron.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1000) and very rare (&lt;1/10,000). Very common, common and uncommon events were generally determined from<s> </s>clinical trial data. The incidence in placebo was taken into account. Rare and very rare<s> </s>events were generally determined from post-marketing spontaneous data.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>The following frequencies are estimated at the standard recommended doses of ondansetron according to indication and formulation. The adverse event profiles in children and adolescents were comparable to that seen in adults.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong><u>Very Common</u></strong></p><p>&ge;1/10</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>&ge;1/100 to &lt;1/10</p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p>&ge;1/1000 to &lt;1/100</p></td><td style="vertical-align:top"><p><strong><u>Rare</u></strong></p><p>&ge;1/10,000 to &lt;1/1000</p></td><td style="vertical-align:top"><p><strong><u>Very rare</u></strong></p><p>&lt;1/10,000</p></td></tr></thead><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Immediate hypersensitivity reactions sometimes severe, including anaphylaxis<sup>1</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Seizures, movement disorders (including extrapyramidal reactions such as dystonic reactions, oculogyric crisis and dyskinesia)<sup>2</sup></p></td><td style="vertical-align:top"><p>Dizziness during rapid IV administration</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Transient visual disturbances (e.g. blurred vision) predominantly during IV administration</p></td><td style="vertical-align:top"><p>Transient blindness predominantly during intravenous administration<sup>3</sup></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Arrhythmias, chest pain with or without ST segment depression, bradycardia</p></td><td style="vertical-align:top"><p>QTc prolongation (including Torsade de pointes)</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Sensation of warmth or flushing</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Hypotension</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Hiccups</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Asymptomatic increases in liver function tests<sup>4</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Toxic skin eruption (including toxic epidermal necrolysis)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Local IV injection site reactions &ndash; in particular by repeated administration</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylaxis can be life-threatening. Hypersensitivity reactions were also observed in patients who have shown these symptoms with other selective 5HT<sub>3</sub> reseptor antagonist.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Observed without definitive evidence of persistent clinical sequelae.</p><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The majority of the blindness cases reported resolved within 20 minutes. Most patients had received chemotherapeutic agents, which included cisplatin. Some cases of transient blindness were reported as cortical in origin.</p><p>&nbsp;</p><p>4. These events were observed commonly in patients receiving chemotherapy with cisplatin.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:39.6pt; margin-right:0cm"><strong>Symptoms and Signs</strong></p><p style="margin-left:39.6pt; margin-right:10.8pt">There is limited experience of ondansetron overdose. In the majority of cases, symptoms were similar to those already reported in patients receiving recommended doses (see section 4.8). Manifestations that have been reported include visual disturbances, severe constipation, hypotension and a vasovagal episode with transient second-degree AV block.</p><p style="margin-left:39.6pt; margin-right:61.2pt">Ondansetron prolongs QT interval in a dose-dependent manner. ECG monitoring is recommended in cases of overdose.</p><p style="margin-left:39.6pt; margin-right:0cm"><strong>Paediatric population</strong></p><p style="margin-left:39.6pt; margin-right:14.4pt">Paediatric cases consistent with serotonin syndrome have been reported after inadvertent oral overdoses of ondansetron (exceeded estimated ingestion of 4 mg/kg) in infants and children aged 12 months to 2 years.</p><p style="margin-left:39.6pt; margin-right:0cm"><!--[if gte vml 1]><v:line
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;z-index:251658752;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 from="48.5pt,786.5pt" to="503.8pt,786.5pt" strokeweight=".7pt">
 <w:wrap anchorx="page" anchory="page"/>
</v:line><![endif]--><!--[if !vml]--><strong>Treatment</strong></p><p style="margin-left:39.6pt; margin-right:43.2pt">There is no specific antidote for ondansetron, therefore in cases of suspected overdose, symptomatic and supportive therapy should be given as appropriate.</p><p style="margin-left:39.6pt; margin-right:21.6pt">The use of ipecacuanha to treat overdose with ondansetron is not recommended, as patients are unlikely to respond due to the anti-emetic action of ondansetron itself.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiemetics and antinauseants, Serotonin (5HT<sub>3</sub>) antagonists</p><p>ATC Code: A04AA01</p><p>&nbsp;</p><p>Ondansetron is a potent, highly selective 5HT<sub>3</sub> receptor antagonist.</p><p>Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT<sub>3</sub> receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT<sub>3</sub> receptors on neurons located both in the peripheral and central nervous system.</p><p>The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.</p><p>Ondansetron does not alter plasma prolactin concentrations.</p><p>The role of ondansetron in opiate-induced emesis is not yet established.</p><p>&nbsp;</p><p>The effect of ondansetron on the QTc interval was evaluated in a double blind, randomized, placebo and positive (moxifloxacin) controlled, crossover study in 58 healthy adult men and women. Ondansetron doses included 8 mg and 32 mg infused intravenously over 15 minutes. At the highest tested dose of 32 mg, the maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction was 19.6 (21.5) msec. At the lower tested dose of 8 mg, the maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction was 5.8 (7.8) msec. In this study, there were no QTcF measurements greater than 480 msec and no QTcF prolongation was greater than 60 msec. No significant changes were seen in the measured electrocardiographic PR or QRS intervals.</p><p><strong><em><u>Paediatric population</u></em></strong></p><p><u>CINV</u></p><p>The efficacy of ondansetron in the control of emesis and nausea induced by cancer chemotherapy was assessed in a double-blind randomised trial in 415 patients aged 1 to 18 years (S3AB3006). On the days of chemotherapy, patients received either ondansetron 5 mg/m<sup>2</sup> intravenous + ondansetron 4 mg orally after 8-12 hrs or ondansetron 0.45 mg/kg intravenous + placebo orally after 8-12 hrs. Post-chemotherapy both groups received 4 m.</p><p>&nbsp;</p><p>ondansetron syrup twice daily for 3 days. Complete control of emesis on worst day of chemotherapy was 49% (5 mg/m<sup>2</sup> intravenous + ondansetron 4 mg orally) and 41% (0.45 mg/kg intravenous + placebo orally). Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 3 days. There was no difference in the overall incidence or nature of adverse events between the two treatment groups.</p><p>A double-blind randomised placebo-controlled trial (S3AB4003) in 438 patients aged 1 to 17 years demonstrated complete control of emesis on worst day of chemotherapy in:</p><p>&bull; 73% of patients when ondansetron was administered intravenously at a dose of 5mg/m<sup>2</sup> together with 2 to 4 mg dexamethasone orally,</p><p>&bull; 71% of patients when ondansetron was administered as syrup at a dose of 8 mg together with 2 to 4 mg dexamethasone orally on the days of chemotherapy.</p><p>Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 2 days. There was no difference in the overall incidence or nature of adverse events between the two treatment groups.</p><p>The efficacy of ondansetron in 75 children aged 6 to 48 months was investigated in an open-label, non-comparative, single-arm study (S3A40320). All children received three 0.15 mg/kg doses of intravenous ondansetron, administered 30 minutes before the start of chemotherapy and then at four and eight hours after the first dose. Complete control of emesis was achieved in 56% of patients.</p><p>Another open-label, non-comparative, single-arm study (S3A239) investigated the efficacy of one intravenous dose of 0.15 mg/kg ondansetron followed by two oral ondansetron doses of 4 mg for children aged &lt; 12 yrs and 8 mg for children aged <!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" alt="GREATER-THAN OR EQUAL TO (8805)"
 style='width:9pt;height:9pt;mso-wrap-distance-left:1.5pt;
 mso-wrap-distance-right:1.5pt'>
 <v:imagedata src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
  o:href="http://renderer.medicines.org.uk/images/entities/GREATER-THAN_OR_EQUAL_TO.gif"/>
</v:shape><![endif]--><img width="12" height="12" alt="GREATER-THAN OR EQUAL TO (8805)" src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />12 years (total no. of children n= 28). Complete control of emesis was achieved in 42% of patients.</p><p><u>PONV</u></p><p>The efficacy of a single dose of ondansetron in the prevention of post-operative nausea and vomiting was investigated in a randomised, double-blind, placebo-controlled study in 670 children aged 1 to 24 months (post-conceptual age <!--[if gte vml 1]><v:shape id="_x0000_i1026" type="#_x0000_t75" alt="GREATER-THAN OR EQUAL TO (8805)"
 style='width:9pt;height:9pt;mso-wrap-distance-left:1.5pt;
 mso-wrap-distance-right:1.5pt'>
 <v:imagedata src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
  o:href="http://renderer.medicines.org.uk/images/entities/GREATER-THAN_OR_EQUAL_TO.gif"/>
</v:shape><![endif]--><img width="12" height="12" alt="GREATER-THAN OR EQUAL TO (8805)" src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />44 weeks, weight <!--[if gte vml 1]><v:shape id="_x0000_i1027" type="#_x0000_t75"
 alt="GREATER-THAN OR EQUAL TO (8805)" style='width:9pt;height:9pt;
 mso-wrap-distance-left:1.5pt;mso-wrap-distance-right:1.5pt'>
 <v:imagedata src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
  o:href="http://renderer.medicines.org.uk/images/entities/GREATER-THAN_OR_EQUAL_TO.gif"/>
</v:shape><![endif]--><img width="12" height="12" alt="GREATER-THAN OR EQUAL TO (8805)" src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />3 kg). Included subjects were scheduled to undergo elective surgery under general anaesthesia and had an ASA status <!--[if gte vml 1]><v:shape id="_x0000_i1028"
 type="#_x0000_t75" alt="LESS-THAN OR EQUAL TO (8804)" style='width:9pt;
 height:9pt;mso-wrap-distance-left:1.5pt;mso-wrap-distance-right:1.5pt'>
 <v:imagedata src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif"
  o:href="http://renderer.medicines.org.uk/images/entities/LESS-THAN_OR_EQUAL_TO.gif"/>
</v:shape><![endif]--><img width="12" height="12" alt="LESS-THAN OR EQUAL TO (8804)" src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />III. A single dose of ondansetron 0.1 mg/kg was administered within five minutes following induction of anaesthesia. The proportion of subjects who experienced at least one emetic episode during the 24-hour assessment period (ITT) was greater for patients on placebo than those receiving ondansetron ((28% vs. 11%, p &lt;0.0001).</p><p>Four double-blind, placebo-controlled studies have been performed in 1469 male and female patients (2 to 12 years of age) undergoing general anaesthesia. Patients were randomised to either single intravenous doses of ondansetron (0.1 mg/kg for paediatric patients weighing 40 kg or less, 4 mg for paediatric patients weighing more than 40 kg; number of patients = 735) or placebo (number of patients = 734). Study drug was administered over at least 30 seconds, immediately prior to or following anaesthesia induction. Ondansetron was significantly more effective than placebo in preventing nausea and vomiting. The results of these studies are summarised in Table 3.</p><p><u>Table 3 Prevention and treatment of PONV in Paediatric Patients &ndash; Treatment response over 24 hours</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:91%"><tbody><tr><td style="vertical-align:top"><p>Study</p></td><td style="vertical-align:top"><p>Endpoint</p></td><td style="vertical-align:top"><p>Ondansetron %</p></td><td style="vertical-align:top"><p>Placebo %</p></td><td style="vertical-align:top"><p>p value</p></td></tr><tr><td style="vertical-align:top"><p>S3A380</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
   coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
   filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" alt="LESS-THAN OR EQUAL TO (8804)"
   style='width:9pt;height:9pt;mso-wrap-distance-left:1.5pt;
   mso-wrap-distance-right:1.5pt'>
   <v:imagedata src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
    o:href="http://renderer.medicines.org.uk/images/entities/LESS-THAN_OR_EQUAL_TO.gif"/>
  </v:shape><![endif]--><img width="12" height="12" alt="LESS-THAN OR EQUAL TO (8804)" src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3GT09</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="_x0000_i1026"
   type="#_x0000_t75" alt="LESS-THAN OR EQUAL TO (8804)" style='width:9pt;
   height:9pt;mso-wrap-distance-left:1.5pt;mso-wrap-distance-right:1.5pt'>
   <v:imagedata src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
    o:href="http://renderer.medicines.org.uk/images/entities/LESS-THAN_OR_EQUAL_TO.gif"/>
  </v:shape><![endif]--><img width="12" height="12" alt="LESS-THAN OR EQUAL TO (8804)" src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3A381</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="_x0000_i1027"
   type="#_x0000_t75" alt="LESS-THAN OR EQUAL TO (8804)" style='width:9pt;
   height:9pt;mso-wrap-distance-left:1.5pt;mso-wrap-distance-right:1.5pt'>
   <v:imagedata src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
    o:href="http://renderer.medicines.org.uk/images/entities/LESS-THAN_OR_EQUAL_TO.gif"/>
  </v:shape><![endif]--><img width="12" height="12" alt="LESS-THAN OR EQUAL TO (8804)" src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3GT11</p></td><td style="vertical-align:top"><p>no nausea</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>0.004</p></td></tr><tr><td style="vertical-align:top"><p>S3GT11</p></td><td style="vertical-align:top"><p>no emesis</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>0.004</p></td></tr></tbody></table><p>CR = no emetic episodes, rescue or withdrawal</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic properties of ondansetron are unchanged on repeat dosing.</p><p>A direct correlation of plasma concentration and anti-emetic effect has not been established.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>A 4&nbsp;mg intravenous infusion of ondansetron given over 5 minutes results in peak plasma concentrations of about 65&nbsp;ng/ml.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The disposition of ondansetron following oral, intramuscular (IM) and intravenous (IV) dosing is similar with a steady state volume of distribution of about 140&nbsp;L. Equivalent systemic exposure is achieved after IM and IV administration of ondansetron.</p><p>Ondansetron is not highly protein bound (70-76%).</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Ondansetron is cleared from the systemic circulation predominantly by hepatic metabolism through multiple enzymatic pathways. The absence of the enzyme CYP2D6 (the debrisoquine polymorphism) has no effect on ondansetron&rsquo;s pharmacokinetics.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Less than 5% of the absorbed dose is excreted unchanged in the urine. Terminal half life is about 3 hours.</p><p>&nbsp;</p><p><u>Special Patient Populations</u></p><p><u>&nbsp;</u></p><p><em>Gender differences</em></p><p>Gender differences were shown in the disposition of ondansetron, with females having a greater rate and extent of absorption following an oral dose and reduced systemic clearance and volume of distribution (adjusted for weight).</p><p><em>Children and Adolescents (aged 1 month to 17 years)</em></p><p style="margin-left:39.6pt; margin-right:7.2pt">In paediatric patients aged 1 to 4 months (n=19) undergoing surgery, weight normalised clearance was approximately 30% slower than in patients aged 5 to 24 months (n=22) but comparable to the patients aged 3 to 12 years. The half-life in the patient population aged 1 to 4 month was reported to average 6.7 hours compared to 2.9 hours for patients in the 5 to 24 month and 3 to 12 year age range. The differences in pharmacokinetic parameters in the 1 to 4 month patient population can be explained in part by the higher percentage of total body&nbsp;</p><p>water in neonates and infants and a higher volume of distribution for water soluble drugs like ondansetron.</p><p>In paediatric patients aged 3 to 12 years undergoing elective surgery with general anaesthesia, the absolute values for both the clearance and volume of distribution of ondansetron were reduced in comparison to values with adult patients. Both parameters increased in a linear fashion with weight and by 12 years of age, the values were approaching those of young adults. When clearance and volume of distribution values were normalised by body weight, the values for these parameters were similar between the different age group populations. Use of weight-based dosing compensates for age-related changes and is effective in normalising systemic exposure in paediatric patients.</p><p>Population pharmacokinetic analysis was performed on 428 subjects (cancer patients, surgery patients and healthy volunteers) aged 1 month to 44 years following intravenous administration of ondansetron. Based on this analysis, systemic exposure (AUC) of ondansetron following oral or IV dosing in children and adolescents was comparable to adults, with the exception of infants aged 1 to 4 months. Volume was related to age and was lower in adults than in infants and children. Clearance was related to weight but not to age with the exception of infants aged 1 to 4 months. It is difficult to conclude whether there was an additional reduction in clearance related to age in infants 1 to 4 months or simply inherent variability due to the low number of subjects studied in this age group. Since patients less than 6 months of age will only receive a single dose in PONV a decreased clearance is not likely to be clinically relevant.</p><p><u>&nbsp;</u></p><p><em>Elderly</em></p><p>&nbsp;</p><p>Early Phase I studies in healthy elderly volunteers showed a slight age-related decrease in clearance, and an increase in half-life of ondansetron. However, wide inter-subject variability resulted in considerable overlap in pharmacokinetic parameters between young (&lt; 65 years of age) and elderly subjects (&ge; 65 years of age) and there were no overall differences in safety or efficacy observed between young and elderly cancer patients enrolled in CINV clinical trials to support a different dosing recommendation for the elderly. Based on more recent ondansetron plasma concentrations and exposure-response modelling, a greater effect on QTcF is predicted in patients &ge;75 years of age compared to young adults. Specific dosing information is provided for patients over 65 years of age and over 75 years of age for IV dosing (see section 4.2).</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>In patients with renal impairment (creatinine clearance 15-60&nbsp;ml/min), both systemic clearance and volume of distribution are reduced following IV administration of ondansetron, resulting in a slight, but clinically insignificant, increase in elimination half-life (5.4&nbsp;h). A study in patients with severe renal impairment who required regular haemodialysis (studied between dialyses) showed ondansetron&rsquo;s pharmacokinetics to be essentially unchanged following IV administration.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>In patients with severe hepatic impairment, ondansetron&rsquo;s systemic clearance is markedly reduced with prolonged elimination half-lives (15-32&nbsp;h).</p><p style="margin-left:39.6pt; margin-right:7.2pt">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data revealed no special hazard for humans based on conventional studies of safety, pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction.</p><p>&nbsp;</p><p>Ondansetron and its metabolites accumulate in the milk of rats, milk/plasma-ratio was 5.2:1.</p><p>&nbsp;</p><p>A study in cloned human cardiac ion channels has shown ondansetron has the potential to affect cardiac repolarisation via blockade of hERG potassium channels. The clinical relevance of this finding is uncertain.<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:12.0pt'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>  </span></span><![endif]--><!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:12.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:43.2pt; margin-right:0cm">Sodium chloride</p><p style="margin-left:43.2pt">Sodium citrate dihydrate<br />Citric acid monohydrate<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ondansetron injection should not be administered in the same syringe or infusion as any other medication.</p><p>&nbsp;</p><p>Ondansetron injection should only be mixed with those infusion solutions that are recommended in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened:  
4 years
Injection:  
After first opening the medicinal product should be used immediately.
Infusion:  
Chemical and physical in-use stability has been demonstrated for 48 hours at 25°C with the
solutions given in section 6.6.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.
The diluted solutions should be stored protected from light.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:43.2pt; margin-right:0cm">Keep the ampoules in the outer carton in order to protect from light.</p><p style="margin-left:43.2pt; margin-right:0cm">For storage conditions of the diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:43.2pt; margin-right:0cm">Type I clear glass ampoules</p><p style="margin-left:43.2pt; margin-right:0cm">2 ml:</p><p style="margin-left:43.2pt; margin-right:0cm">Pack sizes: 1, 5 and 10 ampoules.</p><p style="margin-left:36.0pt; margin-right:0cm">4 ml:</p><p style="margin-left:36.0pt; margin-right:0cm">Pack sizes: 1, 5 and 10 ampoules.</p><p style="margin-left:36.0pt; margin-right:0cm">Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>Ondansetron 2 mg/ml may be diluted with the following solutions for infusion:</p><p>Sodium chloride 9 mg/ml (0.9 % w/v) solution</p><p>Glucose 50 mg/ml (5 % w/v) solution</p><p>Mannitol 100 mg/ml (10 % w/v) solution</p><p>Ringer&rsquo;s lactate solution</p><p>&nbsp;</p><p>The diluted solutions should be stored protected from light.</p><p>&nbsp;</p><p>Note:</p><p>Ondansetron injection ampoules should not be autoclaved.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Labesfal Laboratorios Almiro, S.A 
Zona Industrial do Lagedo, 3465-157 
Santiago de Besteiros
Portugal

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dec 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>